eals , President and CEO of DKBmed. PACE UC educator Steven Ross Brant
, MD, Associate Professor of Medicine and Director of the Meyerhoff Inflammatory Bowel Disease Center at The Johns Hopkins University School of Medicine helped develop the symptom tracking function for both patients and doctors. With the patient's permission, clinicians can log in and track their patient's symptoms and measure adherence.
My Daily PACE is private. All data that a patient enters into My Daily PACE is encrypted, and only he or she can access it and decide who else can view it.
The program is supported by an educational grant from Shire Pharmaceuticals.
DKBmed is an integrated, non-accredited, continuing medical education company operated by a team of experienced medical education. The goal of DKBmed is to provide health care professionals with effective medical education that closes identified knowledge/practice gaps to ensure optimal patient care.
Working with accredited providers, DKBmed develops a range of innovative educational programs and specializes in bringing new adult learning methodologies to the CME landscape. DKBmed was an early adopter of utilizing case scenarios with recorded and live actors, 3D animation, webcasts, podcasts, e-mail, and mobile phone applications for clinicians and patients. These forward-thinking approaches enable users to learn using the latest state-of-the-art techniques and to access educational programs in a manner that is most convenient and appropriate for them.
DKBmed's programs are accessible through the company's web site (www.dkbmed.com). They reach more than 30,000 clinicians specializing in a variety of areas, including neonatology, cystic fibrosis, infectious disease, dermatology, macular degeneration, rheumatoid arthritis, pulmonary disease, nephrology, hematology, transplantation, multiple sclerosPage: 1 2 3 Related medicine technology :1
. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant2
. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD3
. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib4
. Medical Device Daily Wins Prestigious SIPA Award for Outstanding Business Journalism5
. Daily Cocoa Flavanol Consumption Shown to Improve Cognitive Function in Older Adults6
. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA1497
. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe8
. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE9
. Medical Device Daily releases Med-Tech on a Mission: Strategies to Drive Innovation10
. U.S. Census Bureau Daily Feature for November 511
. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan